about
Treating nausea and vomiting in palliative care: a reviewOndansetron oral disintegrating tablets for the prevention of postoperative vomiting in children undergoing strabismus surgery.Ion pair formation as a possible mechanism for the enhancement effect of lauric acid on the transdermal permeation of ondansetron.Ramosetron for the prevention of postoperative nausea and vomiting (PONV): a meta-analysis.Emergency department use of oral ondansetron for acute gastroenteritis-related vomiting in infants and children.Acute gastroenteritis: from guidelines to real lifeOndansetron pharmacokinetics in pregnant women and neonates: towards a new treatment for neonatal abstinence syndrome5-HT3 receptor antagonists for prevention of late acute-onset emesis.Efficacy comparison of ramosetron with ondansetron on preventing nausea and vomiting in high-risk patients following spine surgery with a single bolus of dexamethasone as an adjunct.Clinical practice guidelines on antiemetics in oncology.Acute infectious pediatric gastroenteritis: beyond oral rehydration therapy.Nasal route: an alternative approach for antiemetic drug delivery.Palonosetron for the prevention of chemotherapy-induced nausea and vomiting.Ondansetron: a review of pharmacokinetics and clinical experience in postoperative nausea and vomiting.The Effect of Ondansetron on Acute Opioid Tolerance in Patients Receiving Intrathecal Opioids Prior to Cesarean Delivery.Oral, subcutaneous, and intravenous pharmacokinetics of ondansetron in healthy cats.Granisetron vs ondansetron: is it a question of duration of 5-HT3 receptor blockade?Assessment of ondansetron-associated hypokalemia in pediatric oncology patients.Ondansetron-loaded biodegradable microspheres as a nasal sustained delivery system: in vitro/in vivo studies.Ondansetron-loaded chitosan microspheres for nasal antiemetic drug delivery: an alternative approach to oral and parenteral routes.Drug in adhesive type transdermal matrix systems of ondansetron hydrochloride: optimization of permeation pattern using response surface methodology.Ondansetron Exposure Changes in a Pregnant Woman.Use of an 8(1)3(2) asymmetrical factorial design for the in vitro evaluation of ondansetron permeation through human epidermis.Carbonyl reduction of naltrexone and dolasetron by oxidoreductases isolated from human liver cytosol.L’utilisation de l’ondansétron par voie orale au département d’urgence pour traiter les vomissements aigus liés à la gastroentérite chez les nourrissons et les enfants.Inadvertent spinal injection of ondansetron.Does ondansetron have an effect on intramuscular ketamine-associated vomiting in children? A prospective, randomised, open, controlled study.Comparison of dexamethasone with ondansetron or haloperidol for prevention of patient-controlled analgesia-related postoperative nausea and vomiting: a randomized clinical trial.Antiemetic prophylaxis in thyroid surgery: a randomized, double-blind comparison of three 5-HT3 agents.Limited sampling pharmacokinetics of subcutaneous ondansetron in healthy geriatric cats, cats with chronic kidney disease, and cats with liver disease.Determination of ondansetron and its hydroxy metabolites in human serum using solid-phase extraction and liquid chromatography/positive ion electrospray tandem mass spectrometry.
P2860
Q24635649-A8C50D8E-8F8B-43A1-B79C-642C958EEE2BQ30494478-0BD54EAC-E427-4D95-BFC6-E6699257E7A4Q30967177-DD7DFD6A-E0E1-4BB0-82BA-EDAFA712E049Q34093332-E2C6D4B7-D349-415E-83C0-ED9ECCA69158Q34797725-509E10DC-ED80-4D37-8B89-42065597FAF8Q35026342-529A68AE-2E50-4465-9E85-CD4AFA69BB44Q35075945-E5481C66-50E9-421A-AE86-5314A642DF71Q35865448-7BB2B44A-9341-4ACF-89F2-3AE379C788AFQ36063100-82B69042-BFFB-4103-AB27-7284EE3A1056Q36334870-3EA76969-48B2-4561-82D8-83D32C0CEA86Q36904890-503AE68F-8E4C-44AC-91F0-D696618731E2Q37946545-D85ADEB5-1B27-4FD0-9EB3-0D685FB4E315Q38132238-7BC9EE2D-094F-45E0-ADE1-0D311A9C90BDQ38182638-E4690908-C5EB-4275-93E5-D08F4858EEB0Q40083897-39C8BE1A-958F-4836-91A2-8DBAAA2EE6ABQ40774467-C722FB5F-7F08-439B-808F-A859D5D9199BQ42559540-CE39E27B-BC41-4FB3-B852-453EFA78EC18Q42590441-7E4137D5-FBB8-4A1B-9039-34FB8A3FF0FFQ42717373-5D1636EA-E1A6-484E-BC7B-FAB3066CC65CQ43171584-EE4D6E6F-9431-4831-BA68-54A266238CD6Q43284927-18970B55-0574-45F5-885D-8C9C9E045590Q43736704-065AD48A-782C-4F8E-88C2-385FCD9FD340Q44786249-012AE7DC-F83F-4133-9CDB-054B621FEF47Q45162737-EC26223E-58BA-486B-B092-901924EE0341Q47341086-6E65F002-4F40-47BF-B3DC-408408928C1DQ47384311-AA02F8FB-FB9F-4DA7-AD96-47E5DAA852EBQ47901406-A9DF8EED-589A-4AA7-BBA3-8DB456812B51Q48190618-9042A7DF-C12B-4BDC-977E-0B39401375D3Q48276899-DCD36EEB-C305-483B-9AF4-F032EB943979Q50902457-493472CE-D8FF-4E09-9685-20879D020014Q52070118-924665C5-4DAF-4A8F-AA0B-54851F736254
P2860
description
1995 nî lūn-bûn
@nan
1995年の論文
@ja
1995年学术文章
@wuu
1995年学术文章
@zh-cn
1995年学术文章
@zh-hans
1995年学术文章
@zh-my
1995年学术文章
@zh-sg
1995年學術文章
@yue
1995年學術文章
@zh
1995年學術文章
@zh-hant
name
Ondansetron clinical pharmacokinetics.
@en
type
label
Ondansetron clinical pharmacokinetics.
@en
prefLabel
Ondansetron clinical pharmacokinetics.
@en
P1476
Ondansetron clinical pharmacokinetics.
@en
P2093
P304
P356
10.2165/00003088-199529020-00004
P577
1995-08-01T00:00:00Z
P6179
1019612855